School of Historical and Philosophical Studies - Research Publications
Permanent URI for this collection
Search Results
1 - 10 of 39
-
ItemCollections of paint colour charts, paint tins and paintings as a source for developing an understanding of paint making history(Museums Australia, 2011)A project looking at a collection of painting items from a studio used by the artist Sidney Nolan (1917-1992) from 1951 to 1953 is beginning to grapple with the subject of house paint technology from the pre World War II period up to the mid 1950s. Sidney Nolan was particularly engaged with house paint as an artist’s medium, and it seems sought information from paint makers to obtain a deep technical understanding of these complex paint systems. A number of additional collections of paint material held in Sydney museums have been identified that hold potential to provide new information on paint resins and pigments. A collection of historic paint colour charts which use the paint itself in the swatches of colour, and a collection of early synthetic paint resins from 1934-1937, are both valuable sources for analytical standards and the dating of technologies in Australia.
-
ItemNo Preview AvailablePreserving the Past: How to ensure the development of the conservation profession in Australia is preserved for the future(AICCM, 2011-10-19)The first AICCM conference “Conservation in Australia”, which was held in Canberra in 1976 at the Australian National University, was organised by the few conservators located in Canberra. The intervening 35 years have seen changes in the organisation and conservation profession. This 2011 AICCM National Conference, “Conservation in Australia: Past, Present and Future”, now back in Canberra, will allow us to view where we have come from, and examine the challenges for the future development of the AICCM and Australian conservation profession.
-
ItemNo Preview AvailableConservation in Australian museums(National Museum of Australia, 2011)
-
ItemSearle's wager.(Springer Science and Business Media LLC, 2011-11)Nicholas Agar has recently argued that it would be irrational for future human beings to choose to radically enhance themselves by uploading their minds onto computers. Utilizing Searle's argument that machines cannot think, he claims that uploading might entail death. He grants that Searle's argument is controversial, but he claims, so long as there is a non-zero probability that uploading entails death, uploading is irrational. I argue that Agar's argument, like Pascal's wager on which it is modelled, fails, because the principle that we (or future agents) ought to avoid actions that might entail death is not action guiding. Too many actions fall under its scope for the principle to be plausible. I also argue that the probability that uploading entails death is likely to be lower than Agar recognizes.
-
ItemNo Preview AvailableNeuroethics: A New Way of Doing Ethics.(Informa UK Limited, 2011-03-31)The aim of this article is to argue, by example, for neuroethics as a new way of doing ethics. Rather than simply giving us a new subject matter-the ethical issues arising from neuroscience-to attend to, neuroethics offers us the opportunity to refine the tools we use. Ethicists often need to appeal to the intuitions provoked by consideration of cases to evaluate the permissibility of types of actions; data from the sciences of the mind give us reason to believe that some of these intuitions are less reliable than others. I focus on the doctrine of double effect to illustrate my case, arguing that experimental results suggest that appeal to it might be question-begging. The doctrine of double effect is supposed to show that there is a moral difference between effects that are brought about intentionally and those that are merely foreseen; I argue that the data suggest that we regard some effects as merely foreseen only because we regard bringing them about as permissible. Appeal to the doctrine of double effect therefore cannot establish that there are such moral differences.
-
ItemImpact of the European clinical trials directive on prospective academic clinical trials associated with BMT.(Springer Science and Business Media LLC, 2011-03)The European Clinical Trials Directive (EU 2001; 2001/20/EC) was introduced to improve the efficiency of commercial and academic clinical trials. Concerns have been raised by interested organizations and institutions regarding the potential for negative impact of the Directive on non-commercial European clinical research. Interested researchers within the European Group for Blood and Marrow Transplantation (EBMT) were surveyed to determine whether researcher experiences confirmed this view. Following a pilot study, an internet-based questionnaire was distributed to individuals in key research positions in the European haemopoietic SCT community. Seventy-one usable questionnaires were returned from participants in different EU member states. The results indicate that the perceived impact of the European Clinical Trials Directive has been negative, at least in the research areas of interest to the EBMT.
-
ItemThe case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries(BMC, 2011-10-18)BACKGROUND: Despite the increase in the number of clinical trials in low and middle income countries (LMICs), there has been little serious discussion of whether First in Human (FIH; phase 0 and phase 1) clinical trials should be conducted in LMICs, and if so, under what conditions. Based on our own experience, studies and consultations, this paper aims to stimulate debate on our contention that for products meant primarily for conditions most prevalent in LMICs, FIH trials should preferably be done first in those countries. DISCUSSION: There are scientific and pragmatic arguments that support conducting FIH trials in LMIC. Furthermore, the changing product-development and regulatory landscape, and the likelihood of secondary benefits such as capacity building for innovation and for research ethics support our argument. These arguments take into account the critical importance of protecting human subjects of research while developing capacity to undertake FIH trials. SUMMARY: While FIH trials have historically not been conducted in LMICs, the situation in some of these countries has changed. Hence, we have argued that FIH should be conducted in LMICs for products meant primarily for conditions that are most prevalent in those contexts; provided the necessary protections for human subjects are sufficient.
-
ItemIndian vaccine innovation: the case of Shantha Biotechnics(BMC, 2011-04-20)BACKGROUND: Although the World Health Organization had recommended that every child be vaccinated for Hepatitis B by the early 1980s, large multinational pharmaceutical companies held monopolies on the recombinant Hepatitis B vaccine. At a price as high as USD$23 a dose, most Indians families could not afford vaccination. Shantha Biotechnics, a pioneering Indian biotechnology company founded in 1993, saw an unmet need domestically, and developed novel processes for manufacturing Hepatitis B vaccine to reduce prices to less than $1/dose. Further expansion enabled low-cost mass vaccination globally through organizations such as UNICEF. In 2009, Shantha sold over 120 million doses of vaccines. The company was recently acquired by Sanofi-Aventis at a valuation of USD$784 million. METHODS: The case study and grounded research method was used to illustrate how the globalization of healthcare R&D is enabling private sector companies such as Shantha to address access to essential medicines. Sources including interviews, literature analysis, and on-site observations were combined to conduct a robust examination of Shantha's evolution as a major provider of vaccines for global health indications. RESULTS: Shantha's ability to become a significant global vaccine manufacturer and achieve international valuation and market success appears to have been made possible by focusing first on the local health needs of India. How Shantha achieved this balance can be understood in terms of a framework of four guiding principles. First, Shantha identified a therapeutic area (Hepatitis B) in which cost efficiencies could be achieved for reaching the poor. Second, Shantha persistently sought investments and partnerships from non-traditional and international sources including the Foreign Ministry of Oman and Pfizer. Third, Shantha focused on innovation and quality - investing in innovation from the outset yielded the crucial process innovation that allowed Shantha to make an affordable vaccine. Fourth, Shantha constructed its own cGMP facility, which established credibility for vaccine prequalification by the World Health Organization and generated interest from large pharmaceutical companies in its contract research services. These two sources of revenue allowed Shantha to continue to invest in health innovation relevant to the developing world. CONCLUSIONS: The Shantha case study underscores the important role the private sector can play in global health and access to medicines. Home-grown companies in the developing world are becoming a source of low-cost, locally relevant healthcare R&D for therapeutics such as vaccines. Such companies may be compelled by market forces to focus on products relevant to diseases endemic in their country. Sanofi-Aventis' acquisition of Shantha reveals that even large pharmaceutical companies based in the developed world have recognized the importance of meeting the health needs of the developing world. Collectively, these processes suggest an ability to tap into private sector investments for global health innovation, and illustrate the globalization of healthcare R&D to the developing world.
-
ItemAccess and use of human tissues from the developing world: ethical challenges and a way forward using a tissue trust(BIOMED CENTRAL LTD, 2011-01-25)BACKGROUND: Scientists engaged in global health research are increasingly faced with barriers to access and use of human tissues from the developing world communities where much of their research is targeted. In part, the problem can be traced to distrust of researchers from affluent countries, given the history of 'scientific-imperialism' and 'biocolonialism' reflected in past well publicized cases of exploitation of research participants from low to middle income countries. DISCUSSION: To a considerable extent, the failure to adequately engage host communities, the opacity of informed consent, and the lack of fair benefit-sharing have played a significant role in eroding trust. These ethical considerations are central to biomedical research in low to middle income countries and failure to attend to them can inadvertently contribute to exploitation and erode trust. A 'tissue trust' may be a plausible means for enabling access to human tissues for research in a manner that is responsive to the ethical challenges considered. SUMMARY: Preventing exploitation and restoring trust while simultaneously promoting global health research calls for innovative approaches to human tissues research. A tissue trust can reduce the risk of exploitation and promote host capacity as a key benefit.
-
ItemFranchising Rabies Vaccine Delivery: The Case of Indian Immunologicals(PUBLIC LIBRARY SCIENCE, 2011-04)